| 1 |
Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments[J]. Lancet, 2017, 389(10066): 299-311.
|
| 2 |
Romaszko AM, Doboszynska A. Multiple primary lung cancer: A literature review[J]. Adv Clin Exp Med, 2018, 27(5): 725-730.
|
| 3 |
Tandberg DJ, Tong BC, Ackerson BG, et al. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review[J]. Cancer, 2018, 124(4): 667-678.
|
| 4 |
Wei Z, Yang X, Ye X, et al. Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer[J]. J Cancer Res Ther, 2019, 15(7): 1629-1634.
|
| 5 |
金振兴，杜秀平. 盐酸安罗替尼治疗晚期非小细胞肺癌的临床观察[J]. 临床与病理杂志，2020, 40(4): 905-912.
|
| 6 |
罗详冲，李高峰. PD-1抑制剂卡瑞利珠单抗在晚期恶性肿瘤中的应用进展[J]. 解放军医学杂志，2020, 45(6): 672-679.
|
| 7 |
贺志军，屈红伶，黎阳成，等. 血清肿瘤标志物与血液炎症指标联合检测在非小细胞肺癌的应用价值[J]. 黑龙江医学，2020, 44(7): 957-960.
|
| 8 |
Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study[J]. Br J Cancer, 2018, 119(5): 538-545.
|
| 9 |
Guzik K, Tomala M, Muszak D, et al. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles[J]. Molecules, 2019, 24(11): 2071.
|
| 10 |
Zhou CC, Guang H, Wu FY, et al. A phase Ib study of SHR-1210 plus apatinib for heavily previously treated advanced non-squamous non-small cell lung cancer (NSCLC) patients[J]. Journal of Clinical Oncology, 2018, 36: e21017-e21017.
|
| 11 |
Zhou C, Wang Y, Zhao J, et al. Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with wdvanced nonsquamous NSCLC previously treated with chemotherapy[J]. Clin Cancer Res, 2021, 27(5): 1296-1304.
|
| 12 |
Peng F, Hu D, Lin X, et al. The monocyte to red blood cell count ratio is a strong predictor of postoperative survival in colorectal cancer patients: The Fujian prospective investigation of cancer (FIESTA) study[J]. J Cancer, 2017, 8(6): 967-975.
|
| 13 |
Zou ZY, Liu HL, Ning N, et al. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer[J]. Oncol Lett, 2016, 11(3): 2241-2248.
|
| 14 |
Kasuga I, Makino S, Kiyokawa H, et al. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma[J]. Cancer, 2001, 92(9): 2399-2405.
|
| 15 |
Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: A systematic review and meta-analysis[J]. Ann Surg Oncol, 2016, 23(2): 646-654.
|
| 16 |
Mei Z, Shi L, Wang B, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies[J]. Cancer Treat Rev, 2017, 58: 1-13.
|
| 17 |
代婉婷，刘 云，左 斌，等. 术前外周血中性粒细胞/淋巴细胞比值在评估非小细胞肺癌复发进展中的价值[J]. 巴楚医学，2020, 3(3): 44-48.
|
| 18 |
赵松林，聂秀红. 血清CEA、CYFRA21-1和SCC对晚期非小细胞肺癌化疗效果的评估价值[J]. 标记免疫分析与临床，2018, 25(5): 620-623.
|
| 19 |
段新春，崔 永，龚 民，等. 手术前后血清CEA和CYFRA21-1水平的变化有助于预测非小细胞肺癌患者的预后[J]. 中国肺癌杂志，2015, 18(06): 358-364.
|
| 20 |
孙爱平. NSCLC患者血清CEA、Fer、CA125、CA199变化及临床意义[J]. 当代医学，2020, 26(28): 39-42.
|
| 21 |
王欣欣，黄松洁，于 洋，等. 血清ProGRP、SCCAg及HE4与非小细胞肺癌患者病理特征的关系及其诊断价值分析[J]. 现代生物医学进展，2020, 20(13): 2497-2501.
|
| 22 |
邓勇莹，苏瑞祺，陈宇丽，等. 血清鳞状上皮细胞癌抗原胃泌素释放肽前体细胞角质蛋白19片段抗原21-1在非小细胞肺癌中的表达水平及临床意义[J]. 实用医技杂志，2020, 27(7): 866-868.
|
| 23 |
Lee DS, Park KR, Kim SJ, et al. Serum lactate dehydrogenase levels at presentation in stage Ⅳ non-small cell lung cancer: predictive value of metastases and relation to survival outcomes[J]. Tumour Biol, 2016, 37(1): 619-625.
|
| 24 |
Deng T, Zhang J, Meng Y, et al. Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer[J]. Medicine (Baltimore), 2018, 97(38): e12524.
|